Cite
Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.
MLA
Neuzillet, Yann, et al. “Aggressiveness of Localized Prostate Cancer: The Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.” Hormones & Cancer, vol. 10, no. 1, Feb. 2019, pp. 36–44. EBSCOhost, https://doi.org/10.1007/s12672-018-0351-8.
APA
Neuzillet, Y., Raynaud, J.-P., Dreyfus, J.-F., Radulescu, C., Rouanne, M., Schneider, M., Krish, S., Rouprêt, M., Drouin, S. J., Comperat, E., Galiano, M., Cathelineau, X., Validire, P., Molinié, V., Fiet, J., Giton, F., Lebret, T., & Botto, H. (2019). Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. Hormones & Cancer, 10(1), 36–44. https://doi.org/10.1007/s12672-018-0351-8
Chicago
Neuzillet, Yann, Jean-Pierre Raynaud, Jean-François Dreyfus, Camélia Radulescu, Mathieu Rouanne, Marc Schneider, Sylvie Krish, et al. 2019. “Aggressiveness of Localized Prostate Cancer: The Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.” Hormones & Cancer 10 (1): 36–44. doi:10.1007/s12672-018-0351-8.